糖尿病病中的内源性活性代谢物的网络药理学和分子对接
Xinmiao Xie1, Yanzhe Wang1, Sijia Chen1
1Department of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Renal failure
|December 28, 2023
概括
糖尿病病 (DKD) 的进展是由2 - 基烯酸烯酸甘油 (2-HPG) 和Synaptophysin 1 (SYNJ1) 调节的. 这项研究突出显示了2-HPG/SYNJ1轴在DKD内的细胞脚过程中的保护作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢学 代谢学 代谢学
- 系统生物学 系统生物学
背景情况:
- 糖尿病病 (DKD) 是糖尿病的一种主要并发症,其特征是逐渐恶化的损伤.
- 确定内源性保护性代谢物及其分子机制对于DKD治疗至关重要.
研究的目的:
- 用网络药理学和分子对接来预测和识别DKD中具有保护作用的内源性活性代谢物.
- 阐明在DKD中已识别的代谢物的保护作用背后的分子机制.
主要方法:
- 利用代谢学和蛋白学来选DKD脏组织中差异表达的代谢物和蛋白质.
- 构建了交互网络并进行了通路丰富分析 (GO,信号通路).
- 通过体内和体外实验验验证了候选代谢物的生物功能和下游影响.
主要成果:
- 鉴定出130种不同表达的代谢物,其中2-基基基素 (2-HPG) 作为关键调节剂.
- 证明2-HPG通过调节突触素1 (SYNJ1) 活性 (相关系数0.974) 来调节DKD进展.
- 显示2-HPG治疗恢复了威尔姆斯瘤-1 (WT-1) 在细胞中的表达,并证实了SYNJ1的参与.
结论:
- 在糖尿病脏病中,2-基烯基甘氨酸 (2-HPG) /合成素1 (SYNJ1) 信号轴在保护细胞脚过程中发挥着重要作用.
- 这个轴代表了缓解DKD进展的潜在治疗目标.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
590
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
437
相关概念视频
01:26Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
01:28Renal Drug Excretion: Tubular Secretion
189
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
189
01:22Heart Failure Drugs: Diuretics
388
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:24Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
01:16Protein-Drug Binding: Mechanism and Kinetics
508
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
508